VRD

DRUG3 trials

Sponsors

The First Affiliated Hospital of Soochow University, Institute of Hematology & Blood Diseases Hospital, China, Max Healthcare Insititute Limited

Conditions

Multiple MyelomaValid MeSH Conditions

Phase 1

Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients

RecruitingNCT04025450

The First Affiliated Hospital of Soochow UniversityMultiple Myeloma

Start: 2019-07-15End: 2029-07-15Target: 50Updated: 2019-07-19

Phase 2

A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma

Active, not recruitingNCT05860036

Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma

Start: 2023-04-04End: 2028-03-10Target: 40Updated: 2025-08-03

Unknown Phase

The Effect of Virtual Reality Distraction on Pain During Colonoscopy

CompletedNCT07496333

Max Healthcare Insititute LimitedValid MeSH Conditions

Start: 2023-10-03End: 2024-10-02Updated: 2026-03-27

Related Papers

Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).

2026-02-27

BCMA CAR T-cell therapy in newly diagnosed transplant-ineligible multiple myeloma: An open label, single-arm, phase 2 study (CAREMM-001)

Blood2025-11-03

BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)

Blood2024-11-053 citations